CD274 and neoplasm: Combining CAR T therapy with checkpoint inhibitors with already approved immunotherapies, such as anti-PD-L1 or CAR T cells engineered to secrete PD-1 scFv or nanobodies, promote the anti-tumor activity (97, 198).